Adding Rituxan Boosts Outcomes in HIV-Associated NHLs

ASCO 2012.jpg

According to findings to be reported at the annual meeting of the American Society of Clinical Oncology, outcomes are improved when rituximab is added to standard chemotherapy in patients who are HIV positive and have developed non-Hodgkin's lymphoma.

Researchers from Albert Einstein College of Medicine in New York evaluated 16 clinical trials from the last decade going back to 2000 and involving over 1,100 patients. They sought to determine if there might be some clues to the most effective treatment for NHL patients with HIV, because currently there is no consensus.

Using overall survival, progression-free survival and complete response as primary endpoints, they found that the addition of the monoclonal antibody rituximab could be associated with several factors, notably better rates in:

-- Complete response
-- Progression-free survival
-- Overall survival

Each of the three endpoints. Additionally, the combination chemotherapy regimen EPOCH out-performed CHOP in all three endpoints.

Source: Medpage Today

LymphomaInfo Social